March 20, 2018 Biodesix, Inc. (Boulder, CO, USA), a molecular diagnostics company has entered into a biomarker research collaboration with Checkmate Pharmaceuticals (Cambridge, MA), a clinical-stage biopharmaceutical company focused on developing novel approaches for cancer immunotherapy.
The collaboration will focus on the analysis of the circulating proteome of advanced melanoma patients treated with CMP-001 in combination with pembrolizumab, utilizing ... Read more
March 5, 2018 Scott Hutton Joins Biodesix as Chief Operating Officer, Bringing Two Decades of Medical Industry Experience to Management Team
Boulder, CO, March 5, 2018…Biodesix, Inc., a molecular diagnostics company that develops and commercializes non-invasive, blood-based diagnostic tests for oncology, today announced that the Company increased the size of its offering of its series G preferred shares in ... Read more
January 31, 2018 New PD-L1 Study Data Presented at ASCO-SITC Annual Meeting
Biodesix® announced a new collaboration agreement with PD-L1 expert Professor Fred R. Hirsch, MD, PhD, laboratory director at the Hirsch Biomarker Laboratory at the University of Colorado Cancer Center in Aurora, CO. Dr. Hirsch’s lab will provide analysis of prospectively collected tissue samples with matched plasma from ... Read more
January 19, 2018 WHAT: Dr. Heinrich Roder, Biodesix’ CTO, will speak on “Applied Machine Learning for Immuno-Oncology Diagnostics” in the “AI and Data Science Showcase” track at the Precision Medicine World Conference (PMWC) in Mountain View, CA.
WHO: Heinrich Roder is a company founder and author or co-author of more than 100 publications and talks spanning the fields of ... Read more
December 20, 2017
Boulder, Colo., December 20, 2017 – Findings published in the American Association for Cancer Research (AACR) peer-reviewed journal Cancer Immunology Research demonstrate that a test based on a protein signature associated with patient outcome in metastatic melanoma can effectively predict survival in patients receiving PD-1 blocking antibodies. The test, developed with Biodesix’s proprietary Diagnostic Cortex® ... Read more
December 5, 2017 Biodesix provided updates and data related to the company’s on-market and in-development liquid biopsy tests at the 2017 qPCR & Digital PCR Congress in London, UK this week. The Congress brings together leading global researchers to examine the latest developments, opportunities and applications of both quantitative polymerase chain reaction (PCR) and digital PCR.
According to Congress ... Read more
November 16, 2017 Study results demonstrate equivalency between manual and automated RNA extraction platforms
Biodesix® announced data demonstrating that a novel, automated method for extracting circulating RNA from plasma performed equivalently or better than the established manual method that is currently used for the company’s GeneStrat® test. The data, which resulted from a collaboration between Biodesix and Norgen Biotek, were ... Read more
November 7, 2017 Preliminary Data Indicate Primary Resistance May Be Overcome by Combination Therapies
Boulder, Colorado, November 7, 2017… Biodesix® chief technology officer, Dr. Heinrich Roder, will give an oral presentation discussing a proprietary test development methodology that uses machine learning to correlate MALDI-ToF mass spectra from patient pre-treatment serum with clinical outcomes and benefit from therapy, specifically immunotherapies. The ... Read more
November 1, 2017 ddPCR™ Assay Measures PD-L1, CK19 in mRNA in patients with non-small cell lung cancer
November 1, 2017, Boulder, Colorado… Biodesix® presented preliminary data evaluating a blood-based PD-L1 assay to identify patients who may benefit from cancer immunotherapies. The data were presented last week at the AACR-NCI-EORTC conference. The study was conducted in collaboration with Dr. Michael ... Read more
October 25, 2017 New data on two serum proteomic tests, and an oral presentation on immunotherapy biomarkers
Biodesix will conduct an oral presentation on immunotherapy biomarkers in addition to presenting data from two separate studies at the SITC 2017 Annual Meeting. All three presentations will focus on tests and methods developed via MALDI-ToF mass spectrometry and using the company’s ... Read more